Viridian Therapeutics, Inc./DE Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.27M.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $558.00K, a 76.03% increase year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $561.00K, a 57.58% increase year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $317.00K, a 21.92% increase year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.12M, a 66.02% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for fiscal 2024 was $674.00K, a 16.21% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for fiscal 2023 was $580.00K, a 216.94% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE stock issued during period, value, employee stock purchase plan for fiscal 2022 was $183.00K, a 369.23% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.27M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $1.12M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $558.00K 10-Q · filed 2025-11-05 | |
| 2025-03-31 | $561.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $674.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $317.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $356.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $580.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $260.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $320.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $183.00K 10-K · filed 2025-03-03 | |
| 2022-09-30 | $112.00K 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $71.00K 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $39.00K 10-K · filed 2024-02-27 | |
| 2021-03-31 | $12.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $26.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $10.00K 10-Q · filed 2021-11-05 | |
| 2020-03-31 | $16.00K 10-Q · filed 2021-11-05 | |
| 2019-12-31 | $110.00K 10-K · filed 2021-03-26 | |
| 2019-09-30 | $26.00K 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $84.00K 10-Q · filed 2020-11-12 | $216.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $242.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $132.00K 10-Q · filed 2019-11-08 | $242.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | |
| 2018-03-31 | $110.00K 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $110.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |